Program
nalfurafine
Also written as “IMM02-KORA”, “Remitch®” and “Nalfurafine hydrochloride(MT-9938) 2.5μg”.
Its studies are mostly in Pruritus · Dyskinesias · Kidney Failure, Chronic, led by 6 companies.
Drug pageTRK 820: every studyMany companies study it; this page follows only the 9 they lead. All 12 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Toray Industries | 30 open or running | phase 2since Mar 12, 2008 | Mar 12, 2008 | none ahead |
| SK Chemicalsits history only | 20 open or running | phase 3since Nov 23, 2010 | Nov 23, 2010 | none ahead |
| 3SBioits history only | 10 open or running | phase 3since Jan 26, 2021 | Jan 26, 2021 | none ahead |
| Acologixits history only | 10 open or running | phase 3since Nov 17, 2008 | Nov 17, 2008 | none ahead |
| Immunisits history only | 11 open or running | phase 1since Oct 15, 2026 | Oct 15, 2026 | Dec 30, 2027phase 1 · NCT07905976 |
| Lunan Pharmaceutical Groupits history only | 10 open or running | no phasesince Mar 12, 2026 | Mar 12, 2026 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Toray Industries only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Mar 12, 2008First study: phase 2 study in Pruritus With Chronic Liver DiseaseFirst studyNCT00638495 · 120 enrolled · Japan
- Aug 2, 2012Phase 2 study in PruritusNCT01660243 · 45 enrolled · United States
- Dec 13, 2016Phase 1 study in Uremic PruritusNCT03002233 · 23 enrolled · Bulgaria, Germany
TargetBeta
“Kappa opioid receptor agonist”ChEMBL 37, by rule
Other programs on OPRK1
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Naltrexonerule | orexigen-therapeutics-inc | phase 4 | 42 |
| Nalbuphinerule | Trevi Therapeutics | phase 4 | 21 |
| nalmefenerule | H. Lundbeck | phase 4 | 20 |
| cebranopadolrule | Tris Pharma | phase 3 | 18 |
| Aticaprantrule | Johnson & Johnson | phase 3 | 13 |
| asimadolinerule | tioga-pharmaceuticals | phase 3 | 6 |
| icalcaprant | AbbVie | phase 2 | 6 |
Studies
All 3 Toray Industries leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT03002233Uremic Pruritus · Bulgaria, Germany | 1 | Completed | Jul 2017 | 23 |
| NCT01660243Pruritus · United States | 2 | Terminated | Mar 2014 | 45 |
| NCT00638495Pruritus With Chronic Liver Disease · Japan | 2 | Completed | Dec 2009 | 120 |
How it is read
Names in the registry
- “IMM02-KORA”, 1 entry
- “Remitch®”, 1 entry
- “Nalfurafine hydrochloride(MT-9938) 2.5μg”, 1 entry
- “Nalfurafine hydrochloride(MT-9938) 5μg”, 1 entry
- “Nalfurafine hydrochloride(MT-9938) 10μg”, 1 entry
Conditions, from the studies’ own filings
- Pruritus, 7 studies
- Dyskinesias, 1 study
- Kidney Failure, Chronic, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.